[7] [9] The glucagon receptor component may contribute to increased energy expenditure and fat metabolism, though the human evidence for this effect is still evolving and should not be overstated
If not, pay out-of-pocket, its worth it
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition
Retatrutide is still being evaluated in clinical trials, where researchers are studying its safety, effectiveness, and long-term outcomes
As individuals age, particularly after 35, the efficiency of GLP-1 and GIP signaling can decline significantly
My cholesterol wasnt ideal, either